Overview

A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies

Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The study consists of two stages. In Stage 1, maximum tolerated dose (MTD) will be determined. In Stage 2, additional patients will be treated at the MTD of GDC-0152.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.